Skip to main content

Yuflyma Support Group

Latest news

Celltrion's Yuflyma (adalimumab-aaty) Receives FDA Interchangeability Designation for All Approved Dosage Forms and Strengths

INCHEON, South Korea, May 23, 2025 /PRNewswire/ – Celltrion, Inc. today announced that the U.S. Food and Drug…

Read more news

Ask a question

To post your own question to our community, sign in or create an account.